Surgical treatment of lymph node metastases from hepatocellular carcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 18, Issue 4, 2011, Pages 559-566

  Kobayashi, Shin ^a   Takahashi, Shinichiro ^a   Kato, Yuichiro ^a   Gotohda, Naoto ^a   Nakagohri, Toshio ^a   Konishi, Masaru ^a   Kinoshita, Taira ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Hepatocellular carcinoma; Lymph node metastases; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; BILE LEAKAGE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ESOPHAGUS OBSTRUCTION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; INFERIOR CAVA VEIN OBSTRUCTION; INTESTINE OBSTRUCTION; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MEDICAL RECORD REVIEW; OBSTRUCTIVE JAUNDICE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; SURGICAL APPROACH; SURGICAL INFECTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION;

ABDOMEN; AGED; BIOPSY; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LIVER NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 80052652046     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-011-0372-y     Document Type: Review

References (18)

1. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, et al. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2007;37:676-91. (Pubitemid 47054774)
2. Liver Cancer Study Group of Japan. Primary liver cancer of Japan: clinicopathological features and results of surgical treatment. Ann Surg. 1990;211:277-87.
3. Sun HC, Zhuang PY, Qin LX, Ye QH, Wang L, Ren N, et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol. 2007;96:37-45. (Pubitemid 47015447)
4. Park YJ, Lim DH, Paik SW, Koh KC, Lee JH, Choi MS, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol. 2006;41:1099-106. (Pubitemid 44896725)
5. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs. 2004;15:439-52. (Pubitemid 38736941)
6. Abe T, Furuse J, Yoshino M, Kinoshita T, Konishi M, Inoue K, et al. Clinical characteristics of hepatocellular carcinoma with an extensive lymph node metastasis at diagnosis. Am J Clin Oncol. 2002;25:318-23. (Pubitemid 34602560)
7. Togo S, Takahashi T, Tanaka K, Endo I, Sekido H, Shimada H. Long-term survival in a patients with hepatocellular carcinoma with resection of a metastatic lymph node after percutaneous ethanol injection therapy. Int J Clin Oncol. 2004;9:393-7. (Pubitemid 40012709)
8. Uenishi T, Hirohashi K, Shuto T, Kubo S, Tanaka H, Sakata C, et al. The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma. Surg Today. 2000;30:892-5.
9. Ercolani G, Grazi GL, Ravaioli M, Grigioni WF, Cescon M, Gardini A, et al. The role of lymphadenectomy for liver tumors. Further considerations on the appropriateness of treatment strategy. Ann Surg. 2004;239:202-9. (Pubitemid 38176354)
10. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36. (Pubitemid 43112690)
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55. (Pubitemid 13149996)
12. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
13. Lau H, Man K, Fan ST, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg. 1997;84:1255-9. (Pubitemid 27400276)
14. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer, 1st English edn. Tokyo: Kanehara & Co.; 1997.
15. Zeng ZC, Tang ZY, Fan J, Qin LX, Ye SL, Zhou J, et al. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys. 2005; 63:1067-76. (Pubitemid 41505285)
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:379-90.
17. Cheng AL, Kang YK, Chen Z, Tsao CJ, Kim JS, Luo R, et al. Efficacy and safety of Sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
18. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396-405. (Pubitemid 39657014)